Potentiating the Effects of Radiotherapy in Rectal Cancer: the Role of Aspirin, Statins and Metformin As Adjuncts to Therapy

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Jun 23

PMID 28641310

Citations 18

Authors

K J Gash

A C Chambers

D E Cotton

A C Williams

M G Thomas

Affiliations

Soon will be listed here.

Abstract

Background: Complete tumour response (pCR) to neo-adjuvant chemo-radiotherapy for rectal cancer is associated with a reduction in local recurrence and improved disease-free and overall survival, but is achieved in only 20-30% of patients. Drug repurposing for anti-cancer treatments is gaining momentum, but the potential of such drugs as adjuncts, to increase tumour response to chemo-radiotherapy in rectal cancer, is only just beginning to be recognised.

Methods: A systematic literature search was conducted and all studies investigating the use of drugs to enhance response to neo-adjuvant radiation in rectal cancer were included. 2137 studies were identified and following review 12 studies were extracted for full text review, 9 studies were included in the final analysis.

Results: The use of statins or aspirin during neo-adjuvant therapy was associated with a significantly higher rate of tumour downstaging. Statins were identified as a significant predictor of pCR and aspirin users had a greater 5-year progression-free survival and overall survival. Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients.

Conclusions: Aspirin, metformin and statins are associated with increased downstaging of rectal tumours and thus may have a role as adjuncts to neoadjuvant treatment, highlighting a clear need for prospective randomised controlled trials to determine their true impact on tumour response and overall survival.

Citing Articles

Association of COX-inhibitors with cancer patients' survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis.

Flausino L, Ferreira I, Tuan W, Estevez-Diz M, Chammas R Front Oncol. 2024; 14:1433497.

PMID: 39346725 PMC: 11427433. DOI: 10.3389/fonc.2024.1433497.

Radioproteomics modeling of metformin-enhanced radiosensitivity: an animal study.

Cheki M, Mostafaei S, Hanafi M, Farasat M, Talaiezadeh A, Ghasemi M Jpn J Radiol. 2023; 41(11):1265-1274.

PMID: 37204669 DOI: 10.1007/s11604-023-01445-8.

Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth of murine enteroids.

Sinnett-Smith J, Torres-Marquez M, Chang J, Shimizu Y, Hao F, Martin M Am J Physiol Cell Physiol. 2023; 324(4):C807-C820.

PMID: 36779664 PMC: 10042602. DOI: 10.1152/ajpcell.00286.2022.

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study.

Erkinantti S, Hautakoski A, Sund R, Arffman M, Urpilainen E, Puistola U Biomolecules. 2022; 12(9).

PMID: 36139140 PMC: 9496504. DOI: 10.3390/biom12091301.

Sensitisation of cancer cells to radiotherapy by serine and glycine starvation.

Falcone M, Uribe A, Papalazarou V, Newman A, Athineos D, Stevenson K Br J Cancer. 2022; 127(10):1773-1786.

PMID: 36115879 PMC: 9643498. DOI: 10.1038/s41416-022-01965-6.

References

Giardiello F, Hamilton S, KRUSH A, Piantadosi S, Hylind L, Celano P . Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328(18):1313-6. DOI: 10.1056/NEJM199305063281805. View

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron J . Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894):769-79. PMC: 3778977. DOI: 10.1016/S0140-6736(13)60900-9. View

Nymann T, Jess P, Christiansen J . Rate and treatment of pelvic recurrence after abdominoperineal resection and low anterior resection for rectal cancer. Dis Colon Rectum. 1995; 38(8):799-802. DOI: 10.1007/BF02049834. View

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

Agarwal B, Bhendwal S, Halmos B, Moss S, Ramey W, Holt P . Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999; 5(8):2223-9. View

Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H, Inoue M . Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis. 2003; 20(6):561-7. DOI: 10.1023/a:1025898316728. View

Ryan J, Warrier S, Lynch A, Ramsay R, Phillips W, Heriot A . Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015; 18(3):234-46. DOI: 10.1111/codi.13207. View

10.

Pierotti M, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T . Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2012; 32(12):1475-87. DOI: 10.1038/onc.2012.181. View

11.

Vinogradova Y, Coupland C, Hippisley-Cox J . Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011; 11:409. PMC: 3197575. DOI: 10.1186/1471-2407-11-409. View

12.

Armstrong D, Raissouni S, Hiller J, Mercer J, Powell E, MacLean A . Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. Clin Colorectal Cancer. 2015; 14(4):291-5. DOI: 10.1016/j.clcc.2015.06.001. View

13.

Waddell W, Loughry R . Sulindac for polyposis of the colon. J Surg Oncol. 1983; 24(1):83-7. DOI: 10.1002/jso.2930240119. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Bach S, Hill J, Monson J, Simson J, Lane L, Merrie A . A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009; 96(3):280-90. DOI: 10.1002/bjs.6456. View

17.

Habr-Gama A, Perez R, Proscurshim I, Gama-Rodrigues J . Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am. 2010; 19(4):829-45. DOI: 10.1016/j.soc.2010.08.001. View

18.

Wang L, Hsiao C, Chen W, Lee H, Lin T, Chen H . Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. J Surg Oncol. 2013; 109(6):580-5. DOI: 10.1002/jso.23538. View

19.

Clendening J, Pandyra A, Boutros P, El Ghamrasni S, Khosravi F, Trentin G . Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010; 107(34):15051-6. PMC: 2930553. DOI: 10.1073/pnas.0910258107. View

20.

Schafer W, Kim R, Sterne R, Thorner J, Kim S, Rine J . Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science. 1989; 245(4916):379-85. DOI: 10.1126/science.2569235. View